Pneumococcal Vaccine
Pneumococcal Vaccine is a biological therapy with 23 clinical trials. Currently 4 active trials ongoing. Historical success rate of 94.1%.
Success Metrics
Based on 16 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
9
Mid Stage
10
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
94.1%
16 of 17 finished
5.9%
1 ended early
4
trials recruiting
23
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines
Structured Review: To Optimise Management and Prevent Harm in COPD
Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs
Safety and Immunogenicity of PCV20 in Pediatric Patients With Autoimmune Rheumatic Diseases
Pneumococcal Vaccination in Patients with Anti-TNF Alpha Therapy
Clinical Trials (23)
Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines
Structured Review: To Optimise Management and Prevent Harm in COPD
Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs
Safety and Immunogenicity of PCV20 in Pediatric Patients With Autoimmune Rheumatic Diseases
Pneumococcal Vaccination in Patients with Anti-TNF Alpha Therapy
A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants
Fine Needle aSpiration of Lymph nodEs to Study vAccine-induced Immunity
A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers
Assess the Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine
Study of Immunological Memory Induced in Children by a Full 4 Dose Vaccination Schedule of 11 Valent Pneumococcal Conjugate Vaccine by Giving 1 Dose of Aventis Pasteur's 23-valent Pneumococcal Polysaccharide Vaccine (Pneumo 23)
A Study in Children With Different Formulations of GSK Biologicals' 11 Valent Pneumococcal Conjugate Vaccine
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine.
Immune Memory Evaluation in Children Following a Primary Vaccination With Pneumococcal Conjugate Vaccines.
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine.
A Lot-to-lot Consistency (3 Lots of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine) & Non-inferiority Study
Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488
Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy
PPV: Pneumococcal Polysaccharide Vaccine in Older Adults
Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 23